Condition: Clostridioides Difficile Infection Recurrence · Sponsor: Bactolife A/S
Hospitals and clinics interested in participating in this multi-site study, please contact the people mentioned under "Contacts and Locations". The goal of this study is to map the risk of having a C. Difficile infection recurrence (rCDI) after being treated with standard-of-care antibiotics for a C. Difficile infection. The main questions it aims to answer are: * What is the recurrence rate of CDI in the 8 weeks following antibiotic treatment for a first recurrence of CDI? * Does toxin levels of Toxin A and/or B from C. Diff. at baseline predict CDI recurrence risk? Participants will: * Undergo standard of care Antibiotic treatment for first recurrence of CDI * Visit their clinic at 4 different visits over a time period of approximately 9 weeks. (Visits can also be performed remote/via phone call.)
This description comes directly from the study's public registry record.
Kevin O' Regan Senior Operations Manager, Atlantia Clinical Trials · +1 312 818 8905 · koregan@atlantiatrials.com
Always discuss trial participation with your own doctor first.
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
| Corewell Health William Beaumont University Hospital | Royal Oak, Michigan, United States | Recruiting |
| Mayo Clinic, Minnesota | Rochester, Minnesota, United States | Recruiting |
| University of Wisconsin-Madison | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07250724